



Clontech Licenses CRISPR-Cas9 Technology from Broad Institute

Oct 27, 2014 | [a GenomeWeb staff reporter](#)

NEW YORK (GenomeWeb) – Clontech Laboratories today announced a non-exclusive licensing deal with the Broad Institute for its CRISPR-Cas9 technology.

The deal provides Clontech, a wholly owned subsidiary of Takara Bio, access to the intellectual property surrounding the technology. The US Patent and Trademark Office granted the Broad [the first patent](#) for the CRISPR-Cas9 technology earlier this year.

"We believe that CRISPR-Cas9 technology represents a significant improvement over existing genome editing tools, reaching a new level of targeting, efficiency, and in particular ease of use," Clontech General Manager Carol Lou said in a statement. "It is destined to become as valuable and widely utilized as RNAi — perhaps more so."

Financial and other terms of the deal were not disclosed.

Filed Under

[licensing agreement](#)

[Broad Institute](#)

[gene editing](#)

[Takara](#)

Related Articles

Sep 29, 2016

DuPont Inks CRISPR/Cas9 Deal With International Maize and Wheat Improvement Center

Jun 22, 2016

NIH Panel Approves CRISPR-Edited T Cell Safety Trial, First In-Human Use ■

Jan 04, 2016

In Three Studies, CRISPR Effective in Improving Symptoms of Mice With

Muscular Dystrophy

Nov 10, 2015

USC, Sangamo Scientists Show Improved ZFN Activity in Hematopoietic Stem Cell Genome Editing

Nov 20, 2015

Scientists Develop Assay for Characterizing Editing-Related Features of Novel CRISPR/Cas9 Systems

Sep 19, 2016

UK Opening Five New DNA Synthesis Foundries to Support National Research ■

We recommend

[Sage Licenses CRISPR-Cas9 Technology from Broad Institute](#)

GenomeWeb, 2014

[Broad Institute Licenses CRISPR/Cas9 to AMRI](#)

GenomeWeb, 2016

[Broad Licenses CRISPR/Cas9 IP to GE Healthcare, Sigma-Aldrich](#)

GenomeWeb, 2014

[Horizon Expands CRISPR-Cas9 Portfolio with Broad Institute Licensing Deal](#)

GenomeWeb, 2014

[Evotec Licenses CRISPR Tech From Broad Institute, Harvard](#)

GenomeWeb, 2016

[Bayer Inks CRISPR Patent Licensing Agreement](#)

GenomeWeb, 2016

Powered by **TrendMD**

[Privacy Policy](#). Copyright © 2016 Genomeweb LLC. All Rights Reserved.